Transcript University Of Ottawa Presentation

CTI Life Sciences Fund
Introduction
January 2008
1
CTI Life Sciences Fund - Raison D'être
"Where broad Operational and VC experience come
together to create and realize shareholder value in
Canadian Life Sciences Companies with pre-clinical
and clinical drugs, drug enabling technologies and
medical devices”.
2
CTI Life Sciences Fund – People
Jean-François Leprince -Managing Partner
Accomplished leader with 30 years of multi-products,
multifunctional, multi-geographical experience in the
pharmaceutical industry
Richard Meadows-Managing Partner
VC experience in two multi-billion dollar private equity funds
along with 15+ years Business Development experience in the
pharmaceutical industry
Ken Pastor General Partner’s Representative
20 years experience in the financial market
Shermaine Tilley – Principal
20 years experience in the biotech industry, including
investment management, consulting, tech transfer and
strong academic experience
3
CTI Life Sciences Fund - Investment Objectives
DRUGS, DRUG ENABLING
TECHNOLOGIES, MEDICAL DEVICES
CRITICAL SUCCESS FACTORS
Scientific
Innovation
Financial
objectives
High
Returns
Strategic
objectives
•Value Creation
through Preclinical/POC
Process
•M&A Exits
Goal:
Achieve IRR’s commensurate with ability
to execute strategy
Entrepreneurship/
Leadership
Partnering
with U.S. VC’s
Interacting with
Big Pharmas/
Biotechs
Positioning for Exits
4
CTI Life Sciences Fund - Investment Strategy
Picking the "right" Value Inflection Points
Ph III to market (NDA)
Size of round: $25-50M
Pre-Money $50-100M+
Post-Money: $75-150M
Bump Up: ≈ 3-5 x
Size of round: $1-5M
Pre-Money $5-10M
Post-Money: $6-15 M
Size of round: $5-15M
Pre-Money $10-20M
Post-Money: $15-35M
Bump Up: ≈ 2-3 x
5
CTI Life Sciences Fund
Portfolio Companies
Biopharmaceuticals
Business Description
Development
Stage
Location
Cervelo
Development of Neuropathic, mixed and
inflammatory pain compounds
Phase II
Mississauga
Ontario
Chlorion
Pharma
Development of Neuropathic pain and
Epilepsy compounds
Pre-Clinical
Laval
Québec
Enobia Pharma
Enzyme Replacement Therapy,
Hypophosphatasia as lead program
Pre-Clinical
Montréal
Québec
TargeGen
Leader in kinase inhibitors, applications in
Opthamology, myeloproliferative diseases
and inflammation
Phase II
San Diego
U.S.A.
Lead/Co-Lead
Active Follower
6
CTI Life Sciences Fund Overview
• Emphasis on Quebec & Canadian life sciences
companies, U.S. market opportunistically.
• A highly experienced investment team.
• A unique pro-active exit strategy
Through active post investment management.
Leveraging relationships with top advisors and US VC investors to
position companies for successful exits.
 M&A’s vs. I.P.O’s.


• First Close: CAD $71 million, June 20 2006.
• Target size: CAD $100 million, Achieved March 1 2007
7